

Jeffrey Kern M.D.

Undergraduate: University of Wisconsin, B.S.
Madison, Wisconsin 1975

Medical School: University of Wisconsin
Madison, Wisconsin 1979

Training:

Residency: Parkland Memorial Hospital,
Dallas, Texas

Fellowship Hospital of the University of Pennsylvania
Philadelphia, PA

Cardiovascular-Pulmonary Division

Area of Concentration:

Dr. Kern has been the Chief of the Pulmonary, Critical Care and sleep Medicine Division since 2000. Along with leading the division, he has continued vigorous research activities studying membrane bound tyrosine kinases (RTK) expressed by pulmonary epithelial cells and their role in the regulation of pulmonary epithelial cell proliferation. This work has taken him into fields of lung cancer as well as lung injury and repair. A highly valued component of Dr. Kern's career has been teaching, as he continues to mentor in the laboratory, clinics, and the ICU. He has been a dynamic participant on task forces, committees, and advisory boards and is a recognized reviewer for numerous medical journals as well as being extensively published. He has been awarded "Best Doctors in America" as well as "Top Doc" honors regionally numerous times for his contributions to Pulmonary and Critical Care Medicine.

Recent Publications:

Naeem, N., Eyzaguirre, A, Kern, J.A., Lazarus, H.M., Hejal, R.B., Laughlin, M.J., Kern, E.F.O. Outcome of Adult Umbilical Cord Blood Transplant Patients Admitted to a Medical Intensive Care Unit. *Bone Marrow Transplant*. 2006 Dec; 38(11): 733

Nethery, D, Ghosh, S, Erzurum, S, Kern, J. Inactivation of Neuregulin-1 By Nitration. *Am J Physiol Lung Cell Mol Physiol*. 2007 Jan; 292(1):L287-93

Cortas, T, Eisenberg, R, Fu, P, Kern, J, Patrick, L, Dowlati, A. Activation state egfr and STAT-3 as prognostic markers in resected non-small cell lung cancer. *Lung Cancer*, 2007 Mar; 55(3): 349-55

Yu, Z, Boggon, T, Kobayashi, S, Jin, C, Kern, JA, Tenen, DG, Halmos, B. Resistance to an irreversible EGFR inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. *Cancer Res*. 2007 Nov 1; 67(21):10417-27)

Faress, J, Nethery, D, Kern, JA. Pharmacological blockade of HER2 Attenuates Lung Fibrosis and Improves Survival in Mice. *J Appl Physiol*. 2007 Dec; 103(6):2077-83

Kratzke, RA, Wang, X, Wong, L, G. Kratzke, MG, Green, MR, Vokes, EE, Vogelzang, NJ, Kindler, HL, Kern, JA; for the Cancer, and Leukemia Group B. Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of

p16INK4a, *Results of Cancer and Leukemia Group B 159904* J Thorac Oncol. 2008 Apr; 3(4): 417-21.

Dowlati, A, Kluge, A, Nethery, D, Halmos, B, Kern, JA. SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. *Anti-Cancer Drugs* 19:9–16, 2008